Clinical trials: Ibrutinib
Mantle Cell Lymphoma
Combination of Ibrutinib and Bortezomib to Treat Patients With Mantle Cell Lymphoma
Mantle cell lymphoma (MCL) remains an incurable disease with frequent relapses and no standard therapeutic options in case of relapse. Prolongation of remissions or induction of longer remissions is therefore crucial.
- Trial name
- NCT02356458
- Testing
- Ibrutinib, bortezomib
- Where
- 19 sites in Germany, Italy and 1 more
- Volunteers
- 58 people
- Sponsor
- Swiss Cancer Institute
B-cell Non Hodgkin Lymphoma
Clinical Study of the Safety and Efficacy of the R/R B-NHL Regimen With BTK Inhibitor+Anti-CD19 CAR-T Cells
To evaluate the ORR (CR+PR) of R/R B-NHL subjects treated with BTKi+Anti-CD19 CAR T cells.
- Trial name
- NCT05744037
- Testing
- regimen with BTK inhibitor +Anti-CD19 CAR T cells
- Where
- China
- Volunteers
- 30 people
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Epcoritamab Plus Venetoclax Plus Ibrutinib in Patients With Chronic Lymphocytic Leukemia With TP53 Alterations
This is a phase 2, open-label, multicenter study evaluating the efficacy and safety of a fixed-duration combination of epcoritamab, venetoclax, and ibrutinib (EVI) in previously untreated patients with chronic lymphocytic…
- Trial name
- EVITA (NCT07738887)
- Testing
- Ibrutinib Oral Tablet, Venetoclax Oral Tablet, Epcoritamab
- Where
- 29 sites in Belgium, France
- Volunteers
- 44 people
- Sponsor
- The Lymphoma Academic Research Organisation
Marginal Zone Lymphoma, B-cell Lymphoma
Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed/Refractory Marginal Zone Lymphoma
Phase 2, open-label, non-randomized, monotherapy study to evaluate the safety and efficacy of ibrutinib in subject with relapsed/refractory Marginal Zone Lymphoma (MZL).
- Trial name
- NCT01980628
- Testing
- ibrutinib
- Where
- 25 sites in United States, Belgium and 3 more
- Volunteers
- 63 people
- Sponsor
- Pharmacyclics LLC.
Cancer
Safety and Activity of SNX-5422 Plus Ibrutinib in CLL
SNX-5422 is a prodrug of SNX-2112, a potent, highly selective, small molecule inhibitor of the molecular chaperone heat shock protein 90 (HSP90).
- Trial name
- NCT02914327
- Testing
- SNX-5422 plus ibrutinib
- Where
- United States
- Sponsor
- Esanex Inc.
Leukemia, Lymphocytic, Chronic, B-Cell
Benefits of Individual Physical Activity Intervention on Health-related Quality of Life in Participants With Chronic Lymphocytic Leukemia
The purpose of this study is to assess the impact of an individual physical activity intervention (IPAI) on health-related quality of life (HRQoL) in participants with first line or relapsed chronic lymphocytic leukemia (CLL)…
- Trial name
- QOLIBRI (NCT06299540)
- Testing
- Individual Physical Activity Intervention (IPAI), Ibrutinib
- Where
- France
- Volunteers
- 180 people
- Sponsor
- Janssen Cilag S.A.S.
Mantle-Cell Lymphoma
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (MCL)
This Phase 3 multinational, randomized, double-blind study is designed to compare the efficacy and safety of the combination of ibrutinib and venetoclax vs. ibrutinib and placebo in subjects with MCL.
- Trial name
- SYMPATICO (NCT03112174)
- Testing
- Ibrutinib, Venetoclax
- Where
- 120 sites in United States, Australia and 15 more
- Volunteers
- 366 people
- Sponsor
- Pharmacyclics LLC.
Chronic Lymphocytic Leukemia
Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia
The purpose of this study is to evaluate the impact of sequential overlapping treatment with PD-1 monoclonal antibody (mAb), pembrolizumab/MK-1375, followed by ibrutinib on endogenous immune function in previously untreated…
- Trial name
- NCT03514017
- Testing
- Pembrolizumab, Ibrutinib
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Mantle Cell Lymphoma
Study of Ibrutinib (a Bruton's Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy
The purpose of this study is to evaluate the efficacy and safety of ibrutinib versus temsirolimus in patients with relapsed or refractory mantle cell lymphoma who received at least 1 prior chemotherapy regimen.
- Trial name
- NCT01646021
- Testing
- Ibrutinib, Temsirolimus
- Where
- 92 sites in Belgium, Brazil and 19 more
- Volunteers
- 280 people
- Sponsor
- Janssen Research & Development, LLC
CLL/SLL
A Study of Orelabrutinib in CLL/SLL Patients Who Are Slowly Responding to Ibrutinib
This is a single arm, multi-center study to evaluate the efficacy and safety of orelabrutinib for Chronic lymphocytic lymphoma（CLL)/small lymphocytic lymphoma (SLL) patients who are slowly responding to Ibrutinib switched to…
- Trial name
- NCT05491044
- Testing
- orelabrutinib
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Peking University People's Hospital
Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia
Ibrutinib in Treating Minimal Residual Disease in Patients With Chronic Lymphocytic Leukemia After Front-Line Therapy
This phase II trial studies the side effects and how well ibrutinib works in treating patients with chronic lymphocytic leukemia who responded to initial treatment used to reduce a cancer (front-line therapy) but have residual…
- Conditions
- Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia, Stage IV Chronic Lymphocytic Leukemia
- Trial name
- MERIT (NCT02649387)
- Testing
- Ibrutinib, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Mayo Clinic
Healthy
A Crossover Study to Evaluate the Bioavailability of Ibrutinib Suspension and Sprinkle Formulations Compared to Capsules in Healthy Adults
The purpose of this study is to assess the relative bioavailability (the extent to which a drug or other substance becomes available to the body) of ibrutinib in healthy adults following single oral dose administration of…
- Trial name
- NCT02390609
- Testing
- Ibrutinib (Treatment A) [Reference], Ibrutinib (Treatment B), Ibrutinib (Treatment C)
- Where
- Belgium
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma
Ublituximab + Ibrutinib in Select B-cell Malignancies
The purpose of this study is to evaluate the safety and effectiveness of Ublituximab in combination with Ibrutinib in patients with advanced hematologic malignancies.
- Trial name
- NCT02013128
- Testing
- Ublituximab, Ibrutinib
- Where
- 18 sites in United States
- Volunteers
- 66 people
- Sponsor
- TG Therapeutics, Inc.
Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Marginal Zone Lymphoma
Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone Lymphoma
This phase II trial studies how well ibrutinib in combination with rituximab and lenalidomide works in treating patients with previously untreated, stage II-IV follicular lymphoma or marginal zone lymphoma.
- Conditions
- Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Marginal Zone Lymphoma, Ann Arbor Stage III Follicular Lymphoma, Ann Arbor Stage III Marginal Zone Lymphoma
- Trial name
- NCT02532257
- Testing
- Ibrutinib, Laboratory Biomarker Analysis, Lenalidomide
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- M.D. Anderson Cancer Center
Central Nervous System Lymphoma
LTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma
The purpose of this study is to test the effects of a drug called Voraxaze when it's routinely given in combination with methotrexate and rituximab, the standard treatment for CNSL.
- Trial name
- NCT03684980
- Testing
- Methotrexate, Rituximab, leucovorin
- Where
- 11 sites in United States
- Volunteers
- 58 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Healthy Volunteer
A Study to Assess the Absolute Bioavailability of Oral PCI-32765 and the Effect of Grapefruit Juice on the Bioavailability of PCI-32765 in Healthy Participants
The purpose of this study is to assess the absolute bioavailability of oral PCI-32765 and the effect of grapefruit juice on the absorption of PCI-32765 in healthy adult participants.
- Trial name
- NCT01866033
- Testing
- PCI-32765 (Treatment A), PCI-32765 (Treatment B), PCI-32765 (Treatment C)
- Where
- Belgium
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Lymphoma, Mantle-Cell
Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)
This is a study for participants with a type of blood cancer called mantle cell lymphoma (MCL). The main purpose is to compare pirtobrutinib (LOXO-305) to other drugs that work in a similar way that have already been approved by…
- Trial name
- BRUIN-MCL-321 (NCT04662255)
- Testing
- Pirtobrutinib, Ibrutinib, Acalabrutinib
- Where
- 189 sites in United States, Australia and 22 more
- Volunteers
- 500 people
- Sponsor
- Loxo Oncology, Inc.
Lung Cancer, Nonsmall Cell, Stage I
Study of Ibrutinib Followed by Ibrutinib in Combination With Nivolumab in Non-Small Cell Lung Cancer (NSCLC)
The goal of this clinical research study is to learn if Imbruvica (ibrutinib) alone and then in combination with Opdivo (nivolumab) can control NSCLC in patients who have received previous chemotherapy treatment.
- Trial name
- NCT02950038
- Testing
- Ibrutinib, Nivolumab
- Sponsor
- M.D. Anderson Cancer Center
Indolent Non-Hodgkin Lymphoma
Combination of PCI-32765 With Obinutuzumab in Untreated Follicular Lymphoma
Primary Objectives The primary objective of this study is to evaluate the efficacy of the chemotherapy-free combination of ibrutinib and obinutuzumab (GA 101) in patients with previously untreated follicular lymphoma (FL) and a…
- Trial name
- Alternative (NCT02689869)
- Testing
- Ibrutinib, GA 101
- Where
- Germany
- Volunteers
- 98 people
- Sponsor
- Ludwig-Maximilians - University of Munich
Graft-versus-host Disease (GVHD)
A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)
The purpose of this study is to assess the efficacy of ruxolitinib against best available therapy in participants with steroid-refractory chronic graft-versus-host disease (SR cGvHD).
- Trial name
- NCT03112603
- Testing
- Ruxolitinib, Extracorporeal photopheresis (ECP), Low-dose methotrexate (MTX)
- Where
- 191 sites in United States, Australia and 29 more
- Volunteers
- 330 people
- Sponsor
- Incyte Corporation